Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Addex Therapeutics Ltd
  6. Company
    ADXN   CH0029850754

ADDEX THERAPEUTICS LTD

(ADXN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Logo Addex Therapeutics Ltd
Addex Therapeutics Ltd is a Switzerland-based clinical-stage pharmaceutical company. The Company focuses on development and commercialization of orally available small molecule drugs known as allosteric modulators for neurological disorders. The Company’s clinical programs pipeline include dipraglurant (mGlu5 NAM), which is Phase 2a placebo-controlled clinical trial for Parkinson's disease levodopa-induced dyskinesia (PD-LID), and is being prepared to enter registration trials for PD-LID, and ADX71149 (mGlu2 positive allosteric modulator or PAM), which is being developed in collaboration by its partner Janssen Pharmaceuticals, Inc to treat schizophrenia and anxious depression. It also is advancing several preclinical programs, including GABABPAM for pain, overactive bladder and other disorders, mGlu7 NAM for post-traumatic stress disorder, mGlu2 NAM for mild neurocognitive disorders, mGlu4 PAM for Parkinson’s disease and mGlu3 PAM for neurodegenerative disorders.

Number of employees : 27 people.
Sales per Business
20192020Delta
CHF (in Million)%CHF (in Million)%
Small-molecule Pharmaceutical Products2.83100%3.88106.7% +36.9%
Sales per region
20192020Delta
CHF (in Million)%CHF (in Million)%
Switzerland0.0712.5%0.2667.3% +275.98%
Managers
NameAgeSinceTitle
Timothy Dyer522002Chief Executive Officer & Director
Lénaic Teyssédou-2017Head-Finance
Roger G. Mills, Dr.632017Director & Chief Medical Officer
Jean-Philippe Rocher, Dr.--Head-Discovery Chemistry
Members of the board
NameAgeSinceTitle
Vincent M. Lawton, Dr.71-Chairman
Timothy Dyer522002Chief Executive Officer & Director
Raymond George Hill, Dr.752015Director
Roger G. Mills, Dr.632017Director & Chief Medical Officer
Jake R. Nunn492019Director
Isaac Manke, Dr.--Director
Equities
Vote QuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 49,272,952 39,643,887 80.5% 6,180,083 12.5% 80.5%
Shareholders
NameEquities%
Addex Therapeutics Ltd 15,207,866 30.9%
NEA Management Co. LLC 5,648,690 11.5%
New Leaf Venture Partners LLC 1,897,444 3.85%
Caxton Corp. 1,595,640 3.24%
Credit Suisse Asset Management (Schweiz) AG 1,198,245 2.43%
Laurence W. Lytton 1,188,484 2.41%
Timothy Dyer 435,192 0.88%
Herculis Partners SA 365,137 0.74%
Roger G. Mills 332,501 0.67%
UBS Asset Management Switzerland AG 220,250 0.45%
Holdings
NameEquities%Valuation
Addex Therapeutics Ltd (ADXN) 15,207,86630.9%26,125,745 USD
Company contact information
Addex Therapeutics Ltd.
9, Chemin des Aulx
Plan-les-Ouates
Geneva, Geneve (Geneva) 1202

Phone : +41.22.884.15.55
Fax : +41.22.884.15.56
Web : http://www.addextherapeutics.com
Brand Portfolio
In partnership withAllbrands.markets
More brands of Addex Therapeutics Ltd
Sector Other Biotechnology & Medical Research
1st jan.Capitalization (M$)
ADDEX THERAPEUTICS LTD-22.11%74
MODERNA, INC.102.97%85 140
LONZA GROUP AG13.57%52 316
IQVIA HOLDINGS INC.35.24%46 441
CELLTRION, INC.-22.42%33 893
SEAGEN INC.-10.43%28 470
PHARMARON BEIJING CO., LTD.73.47%25 331
HANGZHOU TIGERMED CONSULTING CO., LTD16.47%25 232
CUREVAC N.V.-29.80%21 497
ALNYLAM PHARMACEUTICALS, INC.34.36%20 527
INCYTE CORPORATION-2.17%18 722
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.46.86%18 440
BIO-TECHNE CORPORATION39.96%17 285
PPD, INC.35.24%16 253
NOVAVAX, INC.72.40%14 239
ICON PUBLIC LIMITED COMPANY8.07%11 139
QIAGEN N.V.-10.48%10 806
PRA HEALTH SCIENCES, INC.32.78%10 792
CRISPR THERAPEUTICS AG-14.65%10 471
GENSCRIPT BIOTECH CORPORATION207.62%8 910
SYNEOS HEALTH, INC.24.75%8 782